@article{b1c7360b6bdc424f9370c2336904d837,
title = "Antisuicidal effects of ketamine: A promising first step",
author = "Trivedi, {Madhukar H.}",
note = "Funding Information: Dr. Trivedi has served as a consultant or advisory board member for Alkermes, Akili Interactive, Allergan Pharmaceuticals, Arcadia Pharmaceuticals, Brintellix Global, Bristol-Myers Squibb, Caudex, Cerecor, Forest Pharmaceuticals, Insys, Johnson & Johnson Pharmaceutical Research and Development, Global Medical Education, Health Research Associates, Lilly Research Laboratories, Lundbeck Research USA, Medscape, Merck, Mitsubishi Pharma, MSI Methylation Sciences, Navitor Pharmaceuticals, Neuronetics, One Carbon Therapeutics, Otsuka America Pharmaceutical, Pamlab, Pfizer, Ridge Diagnostics, Shire Development, Sunovion, and Takeda Global Research; he has received research support from the Agency for Healthcare Research and Quality, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, the National Institute of Diabetes and Digestive and Kidney Diseases, NIMH, NIDA, and the Patient-Centered Outcomes Research Institute; he has received royalties from Janssen Research and Development and honoraria from the American Psychiatric Association, and he has author agreements with Janssen Asia Pacific and Oxford University Press. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.",
year = "2018",
month = feb,
day = "1",
doi = "10.1176/appi.ajp.2017.17111261",
language = "English (US)",
volume = "175",
pages = "97--98",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",
}